#385 скачать в хорошем качестве

#385

Intradetrusor injections of Botulinum toxin A for detrusor overactivity in an office-based setting: efficacy, safety and cost-benefit analysis Fede Spicchiale C1, Martino F2, Pletto S1, Ambrosi Grappelli V1, Amato I1, Pastore S1, Alteri L1, Cavaleri Y1, Farullo G1, Finazzi Agrò E1 1. Department of Urology, Policlinico Tor Vergata, University of Tor Vergata, Rome, 2. University of Tor Vergata, Rome KEYWORDS: Overactive Bladder, Detrusor Overactivity, Quality of Life (QoL) Overactive bladder (OAB) and its related symptoms as urinary frequency, urgency and urge incontinence are mostly due to detrusor overactivity and seem to be highly prevalent in the general population: it has been estimated that almost 11% of the population worldwide suffer from OAB, of which 49 million people only in Europe. OAB has a great impact on the quality of life, can lead to additional medical problems and represents a social and economic burden1. The first line of therapy is pharmacological; whenever patients with OAB do not respond or not tolerate oral therapy, intradetrusor injection of botulinum toxin A (BTX-A) may be considered as an effective treatment option, both for idiopathic and neurogenic OAB2. Although intradetrusor injection of BTX-A seems to be well tolerated, there is a lack of studies on patients’ satisfaction and on safety and efficacy of BTX-A injections performed in the urology clinic3. The aim of this study is to evaluate the safety and efficacy of this treatment in an office-based setting and performing a cost-benefit comparison with the same procedure administered in the operation theatre. Read the full abstract text here: https://www.ics.org/2020/abstract/385